Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 268

1.

Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40.

Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, Peretz T, Lotem M, Gross G.

J Immunol. 2018 Nov 15;201(10):2959-2968. doi: 10.4049/jimmunol.1701725. Epub 2018 Oct 10.

PMID:
30305327
2.

Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer.

Granit RZ, Masury H, Condiotti R, Fixler Y, Gabai Y, Glikman T, Dalin S, Winter E, Nevo Y, Carmon E, Sella T, Sonnenblick A, Peretz T, Lehmann U, Paz K, Piccioni F, Regev A, Root DE, Ben-Porath I.

Cell Rep. 2018 Sep 18;24(12):3237-3250. doi: 10.1016/j.celrep.2018.08.053.

3.

Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.

Yanovich G, Agmon H, Harel M, Sonnenblick A, Peretz T, Geiger T.

Cancer Res. 2018 Oct 15;78(20):6001-6010. doi: 10.1158/0008-5472.CAN-18-1079. Epub 2018 Aug 28.

PMID:
30154156
4.

Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.

Cohen JE, Eleyan F, Zick A, Peretz T, Katz D.

Oncotarget. 2018 Jul 20;9(56):30847-30854. doi: 10.18632/oncotarget.25747. eCollection 2018 Jul 20.

5.

The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.

Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y.

Breast Cancer Res Treat. 2018 Nov;172(1):151-157. doi: 10.1007/s10549-018-4887-7. Epub 2018 Jul 16.

PMID:
30014164
6.

Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.

Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.

Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.

7.

SYK expression level distinguishes control from BRCA1-mutated lymphocytes.

Zahavi T, Sonnenblick A, Shimshon Y, Kadouri L, Peretz T, Salmon AY, Salmon-Divon M.

Cancer Manag Res. 2018 Mar 26;10:589-598. doi: 10.2147/CMAR.S156359. eCollection 2018.

8.

Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy.

Grinshpun A, Gavert N, Granit RZ, Masuri H, Ben-Porath I, Breuer S, Zick A, Rosenberg S, Maoz M, Granit A, Pikarsky E, Strausmman R, Peretz T, Sonnenblick A.

Cancer Biol Ther. 2018 Aug 3;19(8):645-648. doi: 10.1080/15384047.2018.1450114. Epub 2018 Apr 13.

PMID:
29565707
9.

Breast cancer among older women: The influence of age and cancer stage on survival.

Rottenberg Y, Naeim A, Uziely B, Peretz T, Jacobs JM.

Arch Gerontol Geriatr. 2018 May - Jun;76:60-64. doi: 10.1016/j.archger.2018.02.004. Epub 2018 Feb 13.

PMID:
29459246
10.

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A.

Target Oncol. 2018 Apr;13(2):217-226. doi: 10.1007/s11523-017-0548-8.

11.

Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.

Grinshpun A, Halpern N, Granit RZ, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, Peretz T.

Eur J Hum Genet. 2018 Mar;26(3):382-386. doi: 10.1038/s41431-017-0067-1. Epub 2018 Jan 10.

PMID:
29321669
12.

BRCA mutations and reproduction.

Daum H, Peretz T, Laufer N.

Fertil Steril. 2018 Jan;109(1):33-38. doi: 10.1016/j.fertnstert.2017.12.004. Review.

PMID:
29307397
13.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

PMID:
29305520
14.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C.

Int J Oncol. 2018 Feb;52(2):424-432. doi: 10.3892/ijo.2017.4212. Epub 2017 Nov 27.

PMID:
29207087
15.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

16.

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N.

NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017.

17.

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.

Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H.

Medicine (Baltimore). 2017 May;96(20):e6931. doi: 10.1097/MD.0000000000006931.

18.

Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.

Halpern N, Goldberg Y, Kadouri L, Duvdevani M, Hamburger T, Peretz T, Hubert A.

Onco Targets Ther. 2017 Mar 29;10:1889-1896. doi: 10.2147/OTT.S126905. eCollection 2017.

19.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, Peretz T, Goldberg Y.

Gastroenterology. 2017 Jun;152(8):1876-1880.e1. doi: 10.1053/j.gastro.2017.02.014. Epub 2017 Feb 24.

PMID:
28242209
20.

Exclusive destruction of mitotic spindles in human cancer cells.

Visochek L, Castiel A, Mittelman L, Elkin M, Atias D, Golan T, Izraeli S, Peretz T, Cohen-Armon M.

Oncotarget. 2017 Mar 28;8(13):20813-20824. doi: 10.18632/oncotarget.15343.

Supplemental Content

Loading ...
Support Center